AI summary · may contain errors
In 47 primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder samples, PDCD1LG2, MTA3, CCL13, and HDAC3 are overexpressed, shaping a distinct T-follicular helper program.
Moving in JAMA Dermatology, Journal of Investigative Dermatology, Blood, Arthritis & Rheumatology, Journal for ImmunoTherapy of Cancer, Journal of Allergy and Clinical Immunology, Journal of Clinical Oncology and Leukemia.
Rebuilt
Nothing in this topic has moved yet this week.
Newest first · last 60 days
AI summary · may contain errors
In 47 primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder samples, PDCD1LG2, MTA3, CCL13, and HDAC3 are overexpressed, shaping a distinct T-follicular helper program.
AI summary · may contain errors
Nemolizumab is assessed for effectiveness and safety in patients with severe pruritus associated with cutaneous T-cell lymphoma.
AI summary · may contain errors
A woman in her 70s with a 3-year history of extensive coral treelike telangiectasias on the trunk and lower limbs is described after prior diffuse large B-cell lymphoma of the right breast diagnosis.
AI summary · may contain errors
High-dimensional profiling of peripheral blood mononuclear cells in prurigo nodularis shows increased IL-6+TNF-α+ monocytes and elevated serum IL-6 and TNF-α.
AI summary · may contain errors
In 14 patients with Sézary syndrome on mogamulizumab, CD39/CD73/CD38 ectonucleotidase profiles on CD4+ T cells track hematologic disease activity, declining with response and returning at relapse.
AI summary · may contain errors
A 5-marker gene classifier from tape-strip bulk RNA sequencing accurately distinguishes early-stage mycosis fungoides (MF) from both atopic dermatitis (AD) and psoriasis.
AI summary · may contain errors
Tagraxofusp plus azacitidine and venetoclax produced composite complete remission rates of 88% in untreated and 64% in relapsed/refractory BPDCN.
AI summary · may contain errors
Brentuximab vedotin shows the highest pooled overall response rate in advanced cutaneous T-cell lymphomas, achieving 69% (95% CI, 62%–75%) across 510 patients.
AI summary · may contain errors
Dasatinib in relapsed/refractory T follicular helper cell lymphomas produced a 23.5% overall response rate in 17 evaluable patients, below the 30% prespecified endpoint.
AI summary · may contain errors
A single-cell RNA-seq atlas of CTCL from 116 patients (over 2 million skin and blood cells) reveals recurrent malignant T-cell transcriptional programs linked to GATA binding protein 3, especially in large cell transformation and advanced-stage disease.
AI summary · may contain errors
In six patients with severe, treatment-refractory ACPA-positive rheumatoid arthritis, mivocabtagene autoleucel produced CD19+ B-cell depletion with CRS limited to grade 1–2.
AI summary · may contain errors
Response-adapted mosunetuzumab followed by polatuzumab vedotin and obinutuzumab achieved 86% complete response in 42 untreated follicular and marginal zone lymphoma patients.
Journals this month
Topics moving, week to 17 Nov 2026
By field